Trial Profile
Safety of dolutegravir, raltegravir and cobicistat-boosted elvitegravir in HIV infected patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 25 Mar 2022
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary) ; Elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat (Primary) ; Raltegravir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate; Lamivudine/abacavir
- Indications HIV infections
- Focus Adverse reactions
- Acronyms PISCIS
- 16 Feb 2022 Data from the PISCIS cohort of PLWH in Catalonia (Spain) assessing effect of tenofovir alafenamide/emtricitabine (TAF/FTC) and tenofovir disoproxil fumarate/ emtricitabine (TDF/FTC) against SARS-CoV-2 infection and associated clinical outcomes presented at the 29th Conference on Retroviruses and Opportunistic Infections
- 04 Apr 2017 New trial record
- 16 Feb 2017 Results presented at the 24th Conference on Retroviruses and Opportunistic Infections